Ra Medical Systems Announces New Indications

Carlsbad, California, April 5, 2007 -- Ra Medical Systems, Inc., announced today that it received clearance from the FDA to market its PHAROS EX-308 Excimer Laser for two new indications, atopic dermatitis and leukoderma, in addition to psoriasis and vitiligo. Atopic dermatitis is one of the most prevalent skin disorders domestically and internationally, affecting both adults and children with chronic skin inflammation, irritation, and itching. Leukoderma encompasses a variety of conditions that result in depigmented lesions, or “white patches,” including vitiligo, post-inflammatory hypo-pigmented scars, and mature white stretch marks.

“Combined with psoriasis and vitiligo, these two new indications make the PHAROS EX-308 one of the most clinically relevant and versatile tools in a dermatology practice. It offers rapid, painless, non-systemic, and steroid-free treatment for these conditions which affect more than an estimated 5% of the total population,” commented Melissa Burstein, Ra Medical’s Vice President.

“The timing of these indications is ideal as Ra Medical prepares to exhibit at the upcoming American Society for Laser Medicine & Surgery next week,” said Steve Beal, Director of Sales. “Our newly expanded sales force is primed to educate our existing customers about these exciting and meaningful applications as well as communicate the benefits to new customers and their patients.”

“Receiving these indications under FDA 510(k) 062963 is a resounding confirmation of our regulatory capabilities and quality system,” stated Dean Irwin, President. “We are proud of this achievement and look forward to additional growth and expansion in the near future.”

Ra Medical Systems, Inc. Contact: Melissa Burstein, (760-804-1648) ramed.com
Ra Medical Systems, Inc., a privately held emerging medical device company was founded in 2002 to commercialize medical excimer lasers . Based in Carlsbad, CA, the company manufactures and markets excimer laser systems including the EX-308 for the treatment of skin diseases including psoriasis, vitiligo, atopic dermatitis, and leukoderma.

This media release may contain forward-looking statements that constitute Ra Medical Systems' current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. For additional information on factors that could affect Ra Medical’s performance, please call the company directly. Ra Medical Systems expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Ra Medical Systems' expectations or any change in events, conditions, or circumstances on which any such statement is based.